Rockwell Medical (RMTI) Announces Triferic™ Iron Replacement Clinical Data To Be Presented At 14th Asian Pacific Congress Of Nephrology May 14-17, 2014 In Tokyo, Japan
4/29/2014 9:24:11 AM
WIXOM, Mich., April 29, 2014 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (Nasdaq:RMTI), a fully-integrated biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with innovative products and services for the treatment of iron replacement, secondary hyperparathyroidism and hemodialysis, announced today that an oral presentation and poster for Triferic™ will be presented at the 14th Asian Pacific Congress of Nephrology May 14-17, 2014 in Tokyo, Japan. Triferic™ is the Company's late-stage investigational iron-replacement drug for the treatment of iron deficiency in chronic kidney disease patients receiving hemodialysis.
Help employers find you! Check out all the jobs and post your resume.
comments powered by